Hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any constituent of the study medication

Significant acute or chronic bleeding

Hemoglobinopathies (e.g. homozygous sickle-cell disease, thalassemia of all types)

Active malignant disease during the last five years (except non-melanoma skin cancer)

Uncontrolled or symptomatic secondary hyperparathyroidism

Epileptic seizure during the last 6 months

Poorly controlled hypertension (sitting blood pressure \> 170/100 mmHG)

Myocardial infarction or stroke, or severe or unstable CAD

Severe liver disease during the previous 6 months

Congestive heart failure NYHA Class III-IV

Diagnosis or suspicion of pure red cell aplasia (PRCA)

Planned elective surgery during the study period (except cataract surgery and vascular access surgery)

Transfusion of red blood cells during the previous 2 months

Pregnant women

Any contra-indications to Mircera

A Non-Interventional Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease Not on Dialysis